Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma

BACKGROUND: Despite the recent development of new therapies, multiple myeloma (MM) remains an incurable disease. Thus, new, effective treatments are urgently needed, particularly for relapsed or refractory MM (RRMM). In an earlier phase I study, a novel form of recombinant human Apo2L/tumor necrosis...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Chin J Cancer
Hoofdauteurs: Leng, Yun, Qiu, Lugui, Hou, Jian, Zhao, Yaozhong, Zhang, Xuejun, Yang, Shifang, Xi, Hao, Huang, Zhongxia, Pan, Ling, Chen, Wenming
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2016
Onderwerpen:
Original Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5016961/
https://ncbi.nlm.nih.gov/pubmed/27608772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-016-0140-0
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items